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Abstract
Background The prevalence of hypertension continues to rise
in the pediatric population. In recent years, there has been an
increasing amount of reports on serum arginine vasopressin
and its derivative, copeptin, in blood pressure control, but its
role is still unclear. The objective of this study was to assess
serum copeptin in adolescents with essential hypertension.
Methods The study cohort consisted of 84 subjects (30 girls
and 54 boys) aged 11–18 years, divided into two groups:
hypertension (HT) – 53 subjects with confirmed primary
hypertension and R - reference group – 31 subjects in whom
hypertension was excluded on the basis of ambulatory blood
pressure monitoring (ABPM) (white-coat hypertension). Se-
rum copeptin concentration was measured using a commer-
cially available enzyme-linked immunosorbent assay kit
(USCN).
Results Hypertensive patients had higher serum copeptin
levels (median, 267 [Q1–Q3: 151.1–499.7 pg/ml]) than con-
trols (median, 107.3 [Q1–Q3: 36.7–203.4 pg/ml]), (p <0.01).
Statistically significant difference was found both in males and
females. In both groups, positive correlations between serum
copeptin and uric acid levels (r =0.31, p <0.01), albuminuria
(r =0.45, p <0.01), serum triglycerides (r =0.3, p <0.05), body
mass index (BMI) standard deviation score (SDS) (r =0.24,
p <0.05) and 24-h systolic blood pressure (SBP) (r =0.37,
p <0.01) and diastolic blood pressure (DBP) (r =0.23,
p <0.05) were found.
Conclusions In summary, higher serum copeptin levels, a
surrogate for arginine vasopressin (AVP) release, are associ-
ated not only with systolic and diastolic blood pressure but
also with several components of metabolic syndrome includ-
ing obesity, elevated concentration of triglycerides, albumin-
uria, and serum uric acid level. However, for the time being,
more research is needed in order to confirm the role of serum
copeptin as a novel marker of elevated blood pressure and
predictor of metabolic syndrome.
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Introduction
Pediatric hypertension is a lifelong problem that can be pro-
gressive from childhood into adulthood. Recent epidemiologic
data indicate that the prevalence of hypertension has increased.
In a representative sample of the US pediatric population aged
8 to 17 years, Rosner et al. [1] observed an increase in the
prevalence of elevated blood pressure (BP) from National
Health and Nutrition Examination Survey (NHANES) III to
NHANES 1999–2008, with identical BP protocols. In this
period, the risk for having elevated BP, both prehypertension
and hypertension, increased by 27 % [1]. Previous reports by
Ostchega et al. [2] who compared the prevalence of
prehypertension in hypertension between NHANES III and
each of NHANES 1999–2002 and 2003–2006 also confirmed
this trend. The most important reasons are probably increased
prevalence of obesity and higher salt intake in children and
adolescents [1, 3].
The first studies on the role of arginine vasopressin (AVP) in
controlling blood pressure were published in the year 1934 [4].
Since this time, there has been a large volume of published
studies describing its role in hypertension, however the results
have been equivocal. Experimental studies revealed that AVP
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antagonism may reduce arterial pressure in Goldblatt 1 and 2
kidney hypertension [5]. Plasma arginine vasopressin was re-
duced in primary aldosteronism, but elevated in malignant
hypertension [5]. In essential hypertension, there was consid-
erable disagreement among various studies in which plasma
vasopressin or urine vasopressin excretion were measured as to
whether there is evidence for increased secretion of vasopres-
sin. Krakoff et al. [5] did not find any conclusive evidence that
elevated AVP secretion occurs or is necessary for any form of
clinical hypertension. Similarly, Kawano et al. [6] demonstrated
that AVP did not play an important role in mild essential
hypertension through its action on the V1 receptors regardless
of dietary sodium intake. On the contrary, Padfield et al. [7]
demonstrated that abnormal arginine vasopressin concentra-
tions might be caused by hypertension. AVP has also been
implicated as a significant contributor to blood pressure control
in African Americans [8]. Similarly, AVP-dependent changes
were found in elderly people [9], patients with congenital heart
failure [10], or chronic kidney disease [11]. Blood pressure is
regulated by many vasoactive factors. Among them, AVP is
one of the most potent vasoconstrictors and is known to affect
blood pressure by regulating vascular tone and body fluid
through V1aR and/or V2R [12]. It was demonstrated that the
renal vasculature and total renal blood flow are relatively
insensitive to the action of vasopressin on the V1a receptor
under physiological conditions, but in pathological conditions,
a renal vasoconstrictor response is observed. This year, an
interesting paper on a vasopressin-dependent mechanism of
hypertension was published by Littlejohn et al. [13]. The au-
thors suggested that angiotensin-sensitive vasopressin-
producing brain structures are major cardiovascular regulatory
centers, especially in low-renin hypertension. The lack of con-
sensus on the role of vasopressin in essential hypertension may
be the result of the fact that AVP is an unstable molecule both
in vivo and ex vivo. It is rapidly cleared from plasma and is
largely attached to platelets in the circulation. Most vasopressin
assays have relatively limited sensitivity. That is why in recent
years an assay has been developed to measure plasma/serum
copeptin, the C-terminal portion of the precursor of AVP.
Because copeptin has a long half-life and is not bound to
platelets, it is found in considerably higher concentrations in
plasma than AVP and is easily detected with a validated sand-
wich assay. It is considered to be a reliable and clinically useful
surrogate marker for AVP [14]. Copeptin levels correlate to
AVP levels in plasma [15].
In recent years, there has been an increasing amount of
literature on the role of plasma copeptin in metabolic syn-
drome [16], obesity [17], and progression of chronic kidney
disease [18, 19]. However, to the best of our knowledge,
serum copeptin has not been assessed in adolescents with
essential hypertension.
The aim of this study was to test the hypothesis that serum
copeptin (a surrogate marker of AVP) is increased in
adolescents with essential hypertension. Additionally, we
aimed to investigate the correlation between serum copeptin
and clinical, laboratory and ambulatory blood pressure mon-
itoring variables in this group of patients.
Methods
This was a prospective cohort study of hypertensive adoles-
cents. The study included 84 subjects (30 girls and 54 boys),
aged 11–18 years, who were appointed to our unit (Depart-
ment of Pediatrics and Nephrology, TheMedical University of
Bialystok, Poland) betweenMay 2010 and September 2011 in
order to confirm or rule out hypertension. The majority of
subjects were referred to our department by general practi-
tioners after finding elevated casual BP in a primary care
office. On the basis of ambulatory blood pressure monitoring
(ABPM), the examined adolescents were divided into two
groups: hypertension (HT) – 53 subjects with confirmed pri-
mary hypertension and R - reference group – 31 subjects with
white-coat hypertension.
Inclusion criteriawere the following: an age of 11–18 years,
primary arterial hypertension (verified by ABPM - mean 24-h
systolic blood pressure levels greater than or equal to the 95th
percentile for sex and height and systolic blood pressure
(SBP) load greater than 25 %) [20], no clinical or laboratory
signs of infection, normal levels of cortisol, thyroid-
stimulating hormone (TSH) and normal renal function, no
proteinuria, normal electrolyte levels, not having been treated
with antibiotics within the last 4 weeks, and having signed
informed-consent forms.
The following exclusion criteria were used: heart failure,
renal or hepatic dysfunction, diabetes mellitus, systemic in-
flammatory conditions, autoimmune diseases, subjects with
clinical or laboratory signs of secondary hypertension (docu-
mented thyroid, kidney or heart disease, abnormal Doppler of
renal arteries), girls treated with contraceptive pills, patients
treated with hypertensive agents, and medications known to
affect serum uric acid levels and blood pressure values.
The reference group consisted of 31 subjects with normal
blood pressure confirmed in ABPM (mean 24-h systolic blood
pressure levels less than the 95th percentile for sex and height
and SBP load less than 25 %). The participants were term-
born, with normal birth weight, and did not receive any med-
ication at the time of the examination. Family history of
adolescents qualified for this group did not reveal hypertension
or other cardiovascular diseases. History of diabetes or gout
was negative as well. Blood and urine testing including serum
creatinine, urea, serum fasting glucose, lipid profile, and serum
uric acid concentration was within the normal range.
The protocol was approved by the Bioethics Committee of
The Medical University of Bialystok in accordance with the
Declaration of Helsinki. Informed consent was obtained from
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parents of all participants and children older than 16 years of
age.
For all subjects, careful clinical histories were taken and
physical examinations were performed. Body weight and
height were measured using a balance beam scale and pediat-
ric wall-mounted stadiometer and bodymass index (BMI) was
calculated as weight (in kilograms) divided by the square of
height (meters squared). Age- and height-specific reference
values for BMI and height were generated by the LMS meth-
od [21], which characterizes the distribution of a variable by
its median (M), the coefficient of variation (S, i.e., the ratio of
the SD and mean), and skewness (L) required to transform the
data to normality. The LMS values were taken from the OLAF
study, published by Kulaga et al. [22]. Similarly, because the
use of pediatric ABPM reference values is comprised by the
non-Gaussian distribution of 24-h blood pressure in children,
we used the LMS method to calculate SDS values for ABPM.
The reference values of L , M , and S interpolated for the
child’s height from those of the published reference popula-
tion of healthy German children [23].
After an overnight fasting, 5 ml of venous peripheral blood
was collected from each patient and reference for routine
laboratory testing. Isolated serum aliquots were stored at
−80 °C for further analysis. The biochemical work-up includ-
ed serum creatinine, urea, serum fasting glucose, lipid profile,
and serum uric acid concentration.
The serum concentration of copeptin was measured using a
commercially available enzyme-linked immunosorbent assay
(ELISA) kit (USCN) according to the manufacturer’s instruc-
tions. Serum copeptin levels were expressed in pg/ml.
Serum creatinine was determined by Jaffe reaction and uric
acid was assessed using the colorimetric method, both on the
Hitachi apparatus. Serum cholesterol, HDL cholesterol, and
triglycerides were determined by the enzymatic method using
Hitachi 912 Chemistry Analyzer (La Roche Company, Tokyo,
Japan). Serum glucose was measured with the Integra 800
analyzer. Glomerular filtration rate was assessed updated
Schwartz’s formula (GFR), which is recommended in pediat-
ric population [24]. The 24-h urinary albumin excretion rate
(UAER) was analyzed by radioimmunoassay method (RIA).
Albuminuria was considered as 24-h UAER >30 mg/24 h.
Micro- and macroalbuminuria were defined as 24-h UAER
values of 30–300 mg/24 h and >300 mg/24 h, respectively.
Ambulatory blood pressure monitoring (ABPM) was per-
formed by the oscillometric method using Spacelabs Medical
Model 90207 apparatus (Spacelabs Inc, Richmond, Washington,
USA).
The monitors were programmed to measure BP every
15 min during daytime (8:00–22:00) and every 30 min during
nighttime (22:00–8:00), however, the periods were corrected
according to the patients’ diaries. Recording started between
8:00 and 9:00 a.m. and lasted for 24 h. Recordings with a
minimum 80 % of measurement and without break longer
than 2 h were considered sufficient. The mean SBP and
diastolic blood pressure (DBP) were calculated separately
for the 24-h period and for awake and asleep periods. Addi-
tionally, systolic blood pressure load (SBPL) and diastolic
(DBPL) blood pressure load during the day and night was
calculated. HT on the basis of ABPM was defined as mean
systolic BP levels that are ≥95th percentile and LSBP more
than 25 % [20]. Data analysis was performed using the com-
puter program Statistica 10.0 PL (StatSoft, Tulsa, USA).
Discrete variables were expressed as counts (percentage),
whereas continuous variables as median and quartiles, unless
stated otherwise. The comparison between the two groups was
done with the Chi-square and Fisher’s exact tests for categor-
ical variables and t test for continuous variables for normally
distributed data or Mann–Whitney test for the data distributed
not normally. Correlations between copeptin and other vari-
ables (clinical and laboratory parameters) were evaluated by
Pearson’s or Spearman’s test as appropriate in both groups. A
value of p <0.05 was considered statistically significant.
Results
The demographic, clinical, and laboratory data for each group
are summarized in Table 1. Ambulatory blood pressure mon-
itoring and laboratory results were successfully collected from
84 adolescents, 53 hypertensive and 31 with white-coat hy-
pertension (reference group). The median age did not differ
between the groups. Males were more frequently affectedwith
HT than females, consistent with the available reports in the
area [25]. In the examined group, 45 subjects (84.9 %) were
males (M) and eight (15.1 %) were females (F), whereas more
girls (n =22, 71.0 %) than boys (n =9, 29.0 %) were found in
the reference group.
The body height SDS was similar in both groups, however
BMI SDS was significantly higher in hypertensive patients
(p <0.01).
In the HT group, there were 43 patients with hyperuricemia
(serum uric acid level ≥5.5 mg/dl and ten with normouricemia).
Serum levels of fasting glucose, total cholesterol and HDL,
and LDL cholesterol in studied patients did not differ from the
reference group (p >0.05). Serum triglyceride levels were
significantly higher in the HT group (median, 104 mg/dl) than
in the reference group (78 mg/dl)(p <0.05).
When compared to the reference group, hypertensive pa-
tients had higher serum copeptin levels (Table 1). Figure 1
presents a comparison between serum copeptin in the hyper-
tensive and reference groups separately for males and females.
In hypertensive males, the serum copeptin level was signifi-
cantly higher when compared to reference group (median,
269.5 pg/ml [Q1–Q3: 150.1–499.6 pg/ml]) vs. reference (me-
dian, 153.3 [Q1–Q3: 91.0–223.7 pg/ml])(p <0.05). A similar
trend was observed in females. The serum copeptin level in
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HT females was a median of 251.9 [Q1–Q3: 151.1–298.7 pg/
ml]) vs. controls (median, 76.68 [Q1–Q3: 15.85–197.9 pg/
ml]) and the difference was statistically significant (p <0.01).
In both groups, serum copeptin was significantly higher in
males than in females (p <0.05). A statistically significant
positive correlation was observed between serum copeptin
and uric acid levels (r =0.31, p <0.01), albuminuria (r =0.45,
p <0.01), serum triglycerides (r =0.3, p <0.05) and atherogen-
ic ratio (serum triglyceride/HDL cholesterol ratio) (r =0.33,
p <0.05), BMI SDS (r =0.24, p <0.05).
Additionally, a significant positive correlation was also
found between serum copeptin and 24-h SBP SDS (r =0.37,
p <0.01) and 24-h DBP (r =0.23, p <0.05) and nighttime BP
load (SBPL, r =0.37, p <0.01; DBPL, r =0.26, p <0.05)
(Table 2).
The factors that were found to have a significant correlation
with serum copeptin in the single regression analyses were
used as explanatory variables to create the multiple regression
models. In the model (Table 3), three parameters (serum uric
acid, systolic BP, and BMI Z-score) accounted for more than
38.8 % of the variation in the serum copeptin level (p <0.01).
Discussion
The most interesting finding of this cross-sectional study was
that serum copeptin concentration, a surrogate for plasma
AVP release, was significantly higher in hypertensive adoles-
cents in comparison to teenagers in whom diagnosis of hyper-
tension was not confirmed in 24-h ambulatory blood pressure
monitoring (reference group – white-coat hypertension). It is
interesting to note that in both the hypertensive and reference
groups serum copeptin levels were higher than those reported
in the literature in healthy children [26]. A possible explana-
tion for this might be that different methods are used to
measure plasma or serum copeptin level and the results are
given in different units. However, it seems possible that these
results are due to the fact that the reference group in our study
included not healthy teenagers but adolescents with white-
coat hypertension, in whom serum copeptin might be in-
creased. Further studies on a representative group of children
is needed to find reference values for age and gender.
Because there is a significant difference in gender distribu-
tion between patient and reference group, we analyzed serum
copeptin in gender subgroups separately and confirmed in-
creased values both in hypertensive males and females when
Table 1 Anthropometric, clini-
cal, and metabolic characteristics
of the examined group (HT) and
the reference group (R)
BMI body mass index, 24 SBP
24-h systolic blood pressure, 24
DBP 24-h diastolic blood pres-
sure, CRP C-reactive protein,
GFR glomerular filtration rate,
SDS standard deviation score,
HDL high-density lipoprotein
Values are presented as the medi-
an with the interquartile range
(Q1–Q3)
R (31) HT (53) p
Sex (M/F) 9/22 45/8 <0.01
Age (years) 16 (15–17) 17 (16–17) NS
Height SDS 0.04 (−0.95–1.25) 0.33 (−0.54–0.91) NS
BMI SDS 0.00 (−0.44–1.25) 1.32 (0.60–2.36) <0.01
24 SBP SDS 0.10 (−0.88–0.89) 1.68 (0.67–2.62) <0.01
24 DBP SDS 0.21 (−0.53–0.78) 1.17 (0.57–1.79) <0.05
CRP (mg/dl) 0 (0–0.1) 0 (0–0.1) NS
GFR ml/min/1,73 m2 157.4 (143.2–187.9) 145.6 (129.8–155.9) <0.01
Uric acid (mg/dl) 4.58 (3.42–4.84) 6.49 (5.83–7.07) <0.01
Cholesterol (mg/dl) 166.5 (147.0–183.0) 162.0 (139.0–189.0) NS
HDL cholesterol (mg/dl) 52.5 (49.0–60.0) 54.0 (44.0–58.0) NS
Triglyceride (mg/dl) 78 (64–91) 104 (73–163) <0.05
Triglyceride/HDL cholesterol 1.63 (1.22–1.88) 2.00 (1.33–3.45) NS
Glucose (mg/dl) 89 (86–91) 92 (89–95) NS
Albuminuria (mg/24 h) 4.35 (3.12–6.72) 6.13 (3.57–9.3) NS
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Fig. 1 Comparison of serum copeptin in males (a) and females (b)
between hypertensive (HT) and reference (R) group
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compared to reference subgroups. Serum copeptin correlated
positively with both 24-h systolic and diastolic blood pressure
SDS and nighttime blood pressure load. However, no corre-
lations with nocturnal dip in hypertensive patients were ob-
served. To the best of our knowledge, there is no data in the
literature on serum copeptin levels and its correlation with
ambulatory blood pressure monitoring. Another important
finding of this study was that serum copeptin levels were
significantly higher in males than in females. This observation
is consistent with that of Enhorning et al. who found higher
levels of plasma copeptin in men than in women in an adult
population [17]. In an experimental study, AVP secretion was
similar in both male and female mice, however sex-specific
differences in the rate of AVP degradation/clearance were
observed.
Several lines of evidence support a role for AVP in the
pathogenesis of hypertension. Activity of the local tissue RAS
within the brain has been implicated in the development of
hypertension. It was documented in experimental studies that
brain RAS modulates the cardiovascular and fluid-electrolyte
homeostasis not only by interacting with the autonomic ner-
vous system but also by modulating the hypothalamic–pitui-
tary axis and vasopressin release [27].
Two major mechanisms have been proposed that account
for the blood pressure effects of brain angiotensin. First, action
of the RAS within the supraoptic and paraventricular hypo-
thalamic nuclei stimulates the production and release of
arginine vasopressin [28–30]. Second, brain stem actions
of RAS alter baroreflex function sympathetic output [31,
32]. Surprisingly, a population of AVP-expressing neu-
rons appeared to be involved in the regulation of sym-
pathetic nervous activity. It can thus be suggested that
AVP-mediated cross-talk between these two mechanisms
exists.
There are three receptor subtypes known that can bind
vasopressin, theV1a, V1b, and V2 receptors. The V1a and V2
receptors mediate a number of different cellular effects leading
to water conservation. The V1a receptor is localized in smooth
muscle cells, the liver, and kidney (mainly in the interlobular
arteries, the descending vasa recta, the macula densa, and the
collecting duct) [33]. Activation of the V1a receptor results in
an increase in blood pressure by vasoconstriction. This in-
creased vasoconstriction is the result of a direct effect on
smooth muscle cells and of an indirect effect caused by
increased renin secretion [34]. It has also been suggested that
VPmay induce HT byV2 receptor-mediated increased tubular
sodium retention [35, 36]. Additionally, a complex interplay
between V1a−and V2− receptor-mediated effects has been
suggested [35, 37]. Experimental studies showed that chronic
blockade of vasopressin V1a/V2 receptor resulted in normali-
zation of blood pressure in mice [12].
Other important findings were positive correlations be-
tween serum copeptin and body weight, BMI SDS, serum
uric acid, triglycerides levels, TG/HDL ratio (atherogenic
index), and albuminuria.
Association of plasma copeptin and abdominal obesity
was confirmed by Enhorning et al. in adults [16]. It is inter-
esting to note that authors demonstrated that elevated
copeptin predicts the development abdominal obesity,
microalbuminuria and even diabetes mellitus during long
term follow up [16]. The role of AVP in pathogenesis of both
diabetes mellitus and abdominal obesity was described be-
fore; however, it is still not well known. The results of
Enhorning et al.’s study suggested that AVP triggers two
different pathways leading to DM and abdominal obesity.
Independently, however, this fact should be confirmed in
further studies. In this study, we found a strong positive
correlation between serum copeptin and BMI SDS, however
we did not measure waist circumference in our patients.
Serum glucose levels in our patients were normal and did





Age (years) −0.01 NS
BMI Z-score 0.24 <0.05
Serum uric acid (mg/dl) 0.31 <0.01
Serum triglyceride (mg/dl) 0.30 <0.05
Triglyceride/HDL cholesterol ratio 0.32 <0.05
Albuminuria (mg/24 h) 0.45 <0.01
GFR ml/min/1.73 m2 −0.18 NS
24 SBP SDS 0.37 <0.01
24 DBP SDS 0.23 <0.05
Night SBPL (%) 0.37 <0.01
Night DBPL (%) 0.26 <0.05
BMI body mass index, GFR glomerular filtration rate, 24 SBP 24-h
systolic blood pressure, 24 DBP 24-h diastolic blood pressure, SBPL
systolic blood pressure load, DBPL diastolic blood pressure load, SDS
standard deviation score, HDL high-density lipoprotein
Table 3 Multiple linear regres-
sion analysis of the serum
copeptin level
BMI body mass index
Variables Coefficient Standard error 95 % confidence interval p value
Uric acid (mg/dl) −130.285 56.4930 (−243.16; −17.39) 0.03
Systolic blood pressure 7.759 3.6551 (0.46; 15.05) 0.03
BMI Z-score 39.332 16.2896 (6.79; 66.50) 0.01
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not differ with the reference group. No correlation between
serum copeptin and serum glucose levels was found. This
may be caused by the early stage of metabolic syndrome in
our patients. The contribution of AVP to glucose and lipid
metabolism is rather complex. AVP mediates gluconeogene-
sis and glycogenolysis through V1a receptors in the liver [38,
39] and stimulates glucagon or insulin, depending on levels
of glycemia. Additionally, AVP exerts an anti-lipolytic action
[40]. In our cohort, mean serum cholesterol level did not
differ when compared with the reference group, but serum
TG levels were higher in hypertensive patients. Serum
copeptin was significantly associated with higher triglyceride
levels and lower HDL cholesterol levels. The findings of the
current study are consistent with those of Saleem et al. [41]
who found serum copeptin to be independently associated
with several components of metabolic syndrome including
adiposity and dyslipidemia (lower HDL cholesterol and
higher triglyceride levels). In an experimental study, Rossi
et al. [42] demonstrated that intraperitoneal injection of AVP
in goats resulted in an increase in plasma triglyceride levels.
One of the possible explanations for this correlation is in-
creased hepatic synthesis of triglycerides under the influence
of glucocorticoids, glucagon, and epinephrine released under
stress, all of which are up-regulated by AVP [42].
In our study, although albuminuria was not significantly
higher in the HT group, we found a positive correlation with
serum copeptin. An association between these two parameters
was also confirmed by Enhörning et al. [17], however in
elderly people, it might be caused by AVP- mediated changes
of glucose metabolism or blood pressure.
What is interesting is that we also found a statistically
significant positive correlation between serum copeptin and
serum uric acid. It is difficult to explain this result, but it might
be indirectly related to hypertension, which is associated with
hyperuricemia in this group of patients.
Several limitations of our study need to be men-
tioned. This study is limited by its small sample size
and single-center patient population. The study is de-
signed to correlate serum copeptin level values of blood
pressure measured in ambulatory blood pressure moni-
toring. However, in the course of study, we noticed
significant correlations with metabolic syndrome, but
we were not able to relate copeptin to waist circumfer-
ence and HOMA index.
In summary, higher serum copeptin levels, a surrogate
for AVP release, are associated not only with systolic and
diastolic blood pressure but also with several components
of metabolic syndrome including obesity, elevated concen-
tration of triglycerides, albuminuria, and serum uric acid
level. However, for the time being, more research is
needed in order to confirm the role of serum copeptin as
a novel marker of elevated blood pressure and predictor of
metabolic syndrome.
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